Literature DB >> 3947819

Antibody-guided radiolocalisation of tumours in patients with testicular or ovarian cancer using two radioiodinated monoclonal antibodies to placental alkaline phosphatase.

A A Epenetos, D Carr, P M Johnson, W F Bodmer, J P Lavender.   

Abstract

Monoclonal antibodies (H317 and H17E2) against placental-type alkaline phosphatase and testicular placental-like alkaline phosphatase were radiolabelled with 123I or 131I and used in a prospective study of patients with germ-cell neoplasms of the testis (13 studies) or epithelial-origin neoplasms of the ovary (13 studies). The presence of tumour was confirmed in the majority of patients with active disease by antibody scanning. The absence of tumour was confirmed in all cases in patients in complete remission. In two patients with positive antibody scans but no disease found by conventional radiological evaluation, further investigations subsequently revealed the presence of tumour. A positive antibody scan indicates the definite presence of a tumour, although a negative antibody scan does not always exclude the presence of disease. This method may be of clinical value in establishing disease status in patients with potentially curable diseases such as ovarian or testicular cancers.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3947819     DOI: 10.1259/0007-1285-59-698-117

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  8 in total

1.  Imaging of ovarian cancer with radiolabelled monoclonal antibodies.

Authors:  D L van Kranenburg; M J van Kroonenburgh; J B Trimbos; G J Fleuren; E K Pauwels
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

2.  Radioimmunoscintigraphy of ovarian cancer with 131-iodine labeled OC-125 antibody fragments.

Authors:  G Barzen; A C Mayr; M Langer; R Becker; M Cordes; C Zwicker; K Koppenhagen; R Felix
Journal:  Eur J Nucl Med       Date:  1989

Review 3.  Treatment of ovarian cancer: the state of the art.

Authors:  N Einhorn
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

4.  Immunoscintigraphy with 131I-labelled H17E2 monoclonal antibody compared with conventional lymphangiography and computed tomography in the detection of metastases in patients with testicular germ cell tumours.

Authors:  D Pectasides; P Vonorta; A Tsialta-Salihou; K Pateniotis; V Barbounis; H Kayianni; P Arapantoni; J Taylor-Papadimitriou; A Epenetos; P Koutsiouba
Journal:  Br J Cancer Suppl       Date:  1990-07

5.  Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts.

Authors:  S K Sharma; J A Boden; C J Springer; P J Burke; K D Bagshawe
Journal:  Cell Biophys       Date:  1994

6.  Transgenic mice expressing the tumor marker germ cell alkaline phosphatase: an in vivo tumor model for human cancer antigens.

Authors:  S Narisawa; K A Smans; J Avis; M F Hoylaerts; J L Millán
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

7.  Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins.

Authors:  M P Deonarain; A A Epenetos
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

8.  Xenogeneic monoclonal antibodies in the management of cancer: control of their in vivo immunogenicity and induction of specific unresponsiveness using an antibody-drug immunoconjugate.

Authors:  G B Sivolapenko; C Moreno; W Smith; J Corválan; M A Ritter; A A Epenetos
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.